Q1 Earnings Estimate for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Cognition Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period last year, the company earned ($0.27) EPS.

Several other equities research analysts have also issued reports on CGTX. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Chardan Capital lowered their target price on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. Finally, B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $7.50.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.49 on Tuesday. The stock has a market capitalization of $20.35 million, a price-to-earnings ratio of -0.50 and a beta of 1.03. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The business’s fifty day moving average is $0.58 and its 200-day moving average is $0.55.

Hedge Funds Weigh In On Cognition Therapeutics

A number of large investors have recently made changes to their positions in the stock. BIOS Capital Management LP purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $4,208,000. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 211.6% during the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares during the period. Voss Capital LP purchased a new stake in shares of Cognition Therapeutics in the fourth quarter worth about $351,000. Geode Capital Management LLC boosted its position in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares during the period. Finally, Virtu Financial LLC grew its stake in Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after acquiring an additional 22,949 shares in the last quarter. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.